In B-cell lymphomas other than CBCL, TOX deletions, but not expression, were detected in 3/45 patients (7 %) with primary central nervous system lymphomas, and in 2/126 patients (2 %) with acute lymphoblastic leukemia, of which one had a B-precursor phenotype [5, 6, 10]. Here, TOX is linked to B-cell non-Hodgkin lymphoma.